Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• BMO Capital analyst David Lebowitz initiated coverage on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with an Outperform rating and announced a price target of $318. Alnylam Pharmaceuticals closed at $228.61 on Tuesday. See how other analysts view this stock.
• Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage on Agomab Therapeutics NV (NASDAQ:AGMB) with an Overweight rating. AgomAb Therapeutics shares closed at $13.73 on Tuesday. See how other analysts view this stock.
• BMO Capital analyst David Lebowitz initiated coverage on Biomarin Pharmaceutical Inc (NASDAQ:BMRN) with an Outperform rating and announced a price target of $98. BioMarin Pharmaceutical closed at $66.99 on Tuesday. See how other analysts view this stock.
• CLSA analyst Alvin Huang initiated coverage on KE Holdings Inc – ADR (NYSE:BEKE) with an Outperform rating and announced a price target of $23.8. KE Holdings shares closed at $16.87 on Tuesday. See how other analysts view this stock.
• BMO Capital analyst David Lebowitz initiated coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a Market Perform rating and announced a price target of $60. Ionis Pharmaceuticals closed at $59.62 on Tuesday. See how other analysts view this stock.

Considering buying ALNY stock? Here’s what analysts think:

Photo via Shutterstock